Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy.
Bonifacius A, Tischer-Zimmermann S, Santamorena MM, Mausberg P, Schenk J, Koch S, Barnstorf-Brandes J, Gödecke N, Martens J, Goudeva L, Verboom M, Wittig J, Maecker-Kolhoff B, Baurmann H, Clark C, Brauns O, Simon M, Lang P, Cornely OA, Hallek M, Blasczyk R, Seiferling D, Köhler P, Eiz-Vesper B.
Bonifacius A, et al. Among authors: brauns o.
Front Bioeng Biotechnol. 2022 Apr 4;10:867042. doi: 10.3389/fbioe.2022.867042. eCollection 2022.
Front Bioeng Biotechnol. 2022.
PMID: 35480981
Free PMC article.